Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Lab Approved by Pennsylvania

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem today announced that its clinical lab has been approved by Pennsylvania.

The Enzo Clinical Labs is CLIA approved and CAP accredited but in order to operate in Pennsylvania needs separation approval from regulators in that state.

The company also has pending license application in Maine, Maryland, and California.

The license from Pennsylvania is a "significant step in our ability to solicit business and accept specimens from locations" other than the metropolitan New York City area," Kevin Krenitsky, president of Enzo's Clinical Labs division, said in a statement. The lab is also approved by New York state.

"Patient care ins moving increasingly to predictive diagnostics utilizing markers and gene-based programs, and Enzo Clinical Labs, owing to its highly regarded New York state certification, is increasingly focused on developing into a national leader for the application of esoteric testing and the diagnosis of these specimens," Krenitsky said.

The company is developing its ColonSentry colon cancer risk-stratification assay, multiplex DNA sequencing, alternative amplification/detection methods for pathogens, and other diagnostic tests.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.